Prostate Cancer Survival Rates
Published on Feb 11 2010, in the categories: Statistics of Survival Rates
A study, the first of this type, conducted by a team of specialists of the Tropical Hygiene and Medicine school of London, on 1.9 million people in 31 countries, over 20 in Europe, USA, Canada, Australia, Brazil, Japan, Algeria and Cuba, shows that prostate cancer survival rates differs from one country to another. For example, in the USA are registered the best percents, especially among Caucasians.
Scientists compared the prostate cancer survival rates of 5 years between 1990 and 1994. Generally speaking, taking into account all cancer types, the best survival rates were registered in North America, followed by Australia, Japan and Occidental Europe. The smallest survival rates were registered in Algeria, where the scientists could only conduct their studies in the region of Setif.
As for breast and prostate cancer, the best survival rates were registered in the USA. Japan has the best survival rates for colorectal cancer in men, and France- for colorectal cancer in women. The five year survival rate varies from 11.4% in colorectal cancer in men to 38.8% in breast cancer. In the USA, the numbers go from 56.4% in colorectal cancer in men to 91.1 % in prostate cancer. In France, the survival rates go from 52.8% in rectal cancer to 79.8% in breast cancer.
The most significant survival rates are between Occidental Europe, with less than 40% in prostate cancer in Denmark and 80% in Austria for the same type of cancer. In the USA, the survival rate for Afro- Americans than for Caucasians, with a difference of 7% for prostate cancer and 14% for breast cancer. Scientists believe these differences are caused by diagnosis and treatment of doctors.
The presence of three genetic defects influences the prostate cancer survival rates, diminishing the survival rate after the installment of the disease. Because at the time of the diagnosis the doctors are not aware of how the disease is going to evolve (if it is a more aggressive or a slower evolution), the treatment is a decisive aspect.
A simple test could betray the presence of the three genetic defects which would allow doctors to prescribe a more aggressive treatment, which could eventually increase the survival rate of the patient. Statistics show that only 14% of those who have the three genetic defects live for more than 11 years, compared to 85% of those who do not present these three genetic defects.
Unfortunately, there are few patients who present all the three defective genes, according to an article published in the British Journal of Cancer. In Great Britain, from 308 subjects, only 6% presented all the three defective genes. According to Professor Colin Cooper, some prostate cancers evolve so slowly that they will never require treatment, and there are so aggressive types of prostate cancer that they become fatal in no time.
Scientists compared the prostate cancer survival rates of 5 years between 1990 and 1994. Generally speaking, taking into account all cancer types, the best survival rates were registered in North America, followed by Australia, Japan and Occidental Europe. The smallest survival rates were registered in Algeria, where the scientists could only conduct their studies in the region of Setif.
As for breast and prostate cancer, the best survival rates were registered in the USA. Japan has the best survival rates for colorectal cancer in men, and France- for colorectal cancer in women. The five year survival rate varies from 11.4% in colorectal cancer in men to 38.8% in breast cancer. In the USA, the numbers go from 56.4% in colorectal cancer in men to 91.1 % in prostate cancer. In France, the survival rates go from 52.8% in rectal cancer to 79.8% in breast cancer.
The most significant survival rates are between Occidental Europe, with less than 40% in prostate cancer in Denmark and 80% in Austria for the same type of cancer. In the USA, the survival rate for Afro- Americans than for Caucasians, with a difference of 7% for prostate cancer and 14% for breast cancer. Scientists believe these differences are caused by diagnosis and treatment of doctors.
The presence of three genetic defects influences the prostate cancer survival rates, diminishing the survival rate after the installment of the disease. Because at the time of the diagnosis the doctors are not aware of how the disease is going to evolve (if it is a more aggressive or a slower evolution), the treatment is a decisive aspect.
A simple test could betray the presence of the three genetic defects which would allow doctors to prescribe a more aggressive treatment, which could eventually increase the survival rate of the patient. Statistics show that only 14% of those who have the three genetic defects live for more than 11 years, compared to 85% of those who do not present these three genetic defects.
Unfortunately, there are few patients who present all the three defective genes, according to an article published in the British Journal of Cancer. In Great Britain, from 308 subjects, only 6% presented all the three defective genes. According to Professor Colin Cooper, some prostate cancers evolve so slowly that they will never require treatment, and there are so aggressive types of prostate cancer that they become fatal in no time.
If you liked this post, subscribe to our blog by filling your e-mail address below:
Want to add something? Post your comments